|
|
U-Omp19 and alum |
|
Vaxjo ID |
274 |
|
Vaccine Adjuvant Name |
U-Omp19 and alum |
|
Alternative Names |
Brucella spp. protease inhibitor |
|
Adjuvant VO ID |
VO_0005762
|
|
Description |
A bacterial protease inhibitor used as a novel adjuvant, tested in combination with alum in RBD-based COVID-19 vaccine formulations |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
this vaccine formulation conferred protection against an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge of K18-hACE2 mice |
|
Structure |
Protein-based bacterial protease inhibitor |
|
Storage |
Stored at –80°C after purification |
|
Preparation |
Expressed in E. coli, purified, adsorbed to Alhydrogel for formulation |
|
Dosage |
U-Omp19: 100 μg; Alum: 500 μg; Antigen (RBD): 20 μg (prime), 10 μg (boost); intramuscular, 2 doses (Day 0 & 14) |
|
Function |
this vaccine formulation conferred protection against an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge of K18-hACE2 mice |
|
Safety |
No adverse events reported in animal models; safe and well tolerated |
| References |
Coria et al., 2022: Coria LM, Saposnik LM, Pueblas Castro C, Castro EF, Bruno LA, Stone WB, Pérez PS, Darriba ML, Chemes LB, Alcain J, Mazzitelli I, Varese A, Salvatori M, Auguste AJ, Ãlvarez DE, Pasquevich KA, Cassataro J. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. Frontiers in immunology. 2022; 13; 844837. [PubMed: 35296091].
|
|
